2017
DOI: 10.20517/2394-5079.2017.27
|View full text |Cite
|
Sign up to set email alerts
|

Advances in the diagnosis and treatment of liver fibrosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
15
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 20 publications
(15 citation statements)
references
References 34 publications
(34 reference statements)
0
15
0
Order By: Relevance
“…HCC surveillance was done every 6 to 12 months by ultrasound and alpha-fetoprotein (AFP) testing under the Hospital Authority. APRI, FIB-4, and Forns index were calculated as described ( Supplementary Table 1 ) [ 15 , 25 , 26 ]. We excluded the following patients: those co-infected with hepatitis C virus and/or hepatitis D virus based on ICD-9-CM diagnosis codes, viral and serological markers and/or use of antiviral therapy for hepatitis C; co-infected with human immunodeficiency virus based on ICD-9-CM diagnosis codes and/or use of antiviral therapy for human immunodeficiency virus; had other coexisting autoimmune and metabolic liver diseases based on ICD-9-CM diagnosis codes; had cancer including HCC and/or liver transplantation before or within the first 6 months after baseline date; follow-up duration less than 6 months; received rituximab and any chemotherapeutic agents ( Supplementary Tables 1 , 2 ).…”
Section: Methodsmentioning
confidence: 99%
See 3 more Smart Citations
“…HCC surveillance was done every 6 to 12 months by ultrasound and alpha-fetoprotein (AFP) testing under the Hospital Authority. APRI, FIB-4, and Forns index were calculated as described ( Supplementary Table 1 ) [ 15 , 25 , 26 ]. We excluded the following patients: those co-infected with hepatitis C virus and/or hepatitis D virus based on ICD-9-CM diagnosis codes, viral and serological markers and/or use of antiviral therapy for hepatitis C; co-infected with human immunodeficiency virus based on ICD-9-CM diagnosis codes and/or use of antiviral therapy for human immunodeficiency virus; had other coexisting autoimmune and metabolic liver diseases based on ICD-9-CM diagnosis codes; had cancer including HCC and/or liver transplantation before or within the first 6 months after baseline date; follow-up duration less than 6 months; received rituximab and any chemotherapeutic agents ( Supplementary Tables 1 , 2 ).…”
Section: Methodsmentioning
confidence: 99%
“…APRI, FIB-4 and Forns index were calculated as described (Supplementary Table 1). 15,25,26 We excluded the following patients: those co-infected with hepatitis C virus and/or hepatitis D virus based on ICD-9-CM diagnosis codes, viral and serological markers and/or use of antiviral therapy for hepatitis C; co-infected with human immunodeficiency virus based on ICD-9-CM diagnosis codes and/or use of antiviral therapy for human immunodeficiency virus; had other coexisting autoimmune and metabolic liver diseases based on ICD-9-CM diagnosis codes; had cancer including HCC and/or liver transplantation before or within the first six months after baseline date; follow-up duration less than six months; received rituximab and any chemotherapeutic agents (Supplementary Tables 1-2). We also excluded patients with ICD-9-CM diagnosis codes of acute hepatitis B and/or positive immunoglobulin M to hepatitis B core antigen unless it was more than six months apart from a positive hepatitis B surface antigen result, patients with Child-Pugh class B or C or had any hepatic events before baseline.…”
Section: Subjectsmentioning
confidence: 99%
See 2 more Smart Citations
“…Liver fibrosis disrupts normal parenchyma of liver structure producing collagenous scar that finally could lead to liver cirrhosis and hepatocellular carcinoma (HCC), end-stage of liver disease; this initiates a calamity in liver tissue and occurs as a response for the noxious stimuli causing chronic liver diseases, such as viral infection, alcoholic consumption, autoimmune disease, and fatty liver ( 1 , 2 ). Liver cirrhosis and HCC have contributed to 2.5% of premature deaths worldwide, and more than 300 million people are diagnosed having one of the chronic liver diseases with viral hepatitis as the leading cause.…”
Section: Introductionmentioning
confidence: 99%